August 14, 2020
Fitch Even partner Steven G. Parmelee is coauthor of the newly released book The Essentials of Japanese Patent Prosecution, published by the ABA Section of Intellectual Property Law. Steve worked with Japanese patent attorney Shinsuke Ohnuki and patent attorney/translator Hideko Yamamoto to update and expand the best-selling Japanese version of the book of the same title, which was written by Shinsuke and is now in its fourth edition.
The book is a comprehensive and practical examination of the Japanese patent prosecution process. As Steve writes in the book’s preface, “There is both law and sage practical counsel here. There are definitions, explanations, historical context, examples, and a rich offering of well-chosen court decisions that guide, inform, and exemplify [Shinsuke’s] points.” Topics include how to work with the Japan Patent Office (JPO), reasons the JPO rejects applications, and how to respond to JPO official actions to patent practitioners.
In addition, Steve provides detailed commentary interspersed throughout the text that compares and contrasts various points of Japanese procedure with U.S. patent practice. These insertions provide guidance for situations when Japanese practice tracks with and when it departs from what is familiar to U.S. practitioners. Understanding how the Japanese patent system operates can greatly help U.S. practitioners to assist their Japanese counterparts in obtaining better results, in less time, and at reduced cost.
To learn more about this book and review a detailed table of contents and sample chapter, please visit the ABA bookstore.
IP Alert | Stock Ownership Leads to Vacatur of $2.75B District Court JudgmentAugust 8, 2022
On June 23, in Centripetal Networks v. Cisco Systems, the Federal Circuit vacated judgment of the district court because stock held by the judge's wife violated the recusal statute and was not harmless error. Read more
IP Alert | Rehearing Reverses Earlier Federal Circuit Decision Finding Silence Supported Negative Claim LimitationJuly 6, 2022
On June 21, in Novartis Pharmaceuticals Corporation v. Accord Healthcare, Inc., a reshuffled Federal Circuit panel reversed course on rehearing to find that a negative claim limitation was not supported by silence in the patent's specification. Read more